C. albicans growth, transition, biofilm formation, and gene expression modulation by antimicrobial decapeptide KSL-W

BMC Microbiology

Mahmoud Rouabhia²  Kai P Leung³  Abdullah Alamri²  Abdelhabib Semlali¹  Simon Theberge² 

[1] Department of Biochemistry, Genome Research Chair, College of Science King Saud University, Riyadh, Kingdom of Saudi Arabia;Oral Ecology Research Group, Faculty of Dentistry, Laval University, 2420, rue de la Terrasse, Quebec G1V 0A6, QC, Canada;Dental and Trauma Research Detachment, US Army Institute of Surgical Research, JBSA Fort Sam Houston, San Antonio, TX, USA

关键词: SAPs;    HWP1;    NRG1;    EFG1;    Gene;    Hyphae;    Growth;    C. albicans;    KSL-W;    Antimicrobial peptide;   

Others  :  1142775
DOI  :  10.1186/1471-2180-13-246

 received in 2013-07-05, accepted in 2013-11-04,  发布年份 2013

【 摘 要 】

Background

Antimicrobial peptides have been the focus of much research over the last decade because of their effectiveness and broad-spectrum activity against microbial pathogens. These peptides also participate in inflammation and the innate host defense system by modulating the immune function that promotes immune cell adhesion and migration as well as the respiratory burst, which makes them even more attractive as therapeutic agents. This has led to the synthesis of various antimicrobial peptides, including KSL-W (KKVVFWVKFK-NH₂), for potential clinical use. Because this peptide displays antimicrobial activity against bacteria, we sought to determine its antifungal effect on C. albicans. Growth, hyphal form, biofilm formation, and degradation were thus examined along with EFG1, NRG1, EAP1, HWP1, and SAP 2-4-5-6 gene expression by quantitative RT-PCR.

Results

This study demonstrates that KSL-W markedly reduced C. albicans growth at both early and late incubation times. The significant effect of KSL-W on C. albicans growth was observed beginning at 10 μg/ml after 5 h of contact by reducing C. albicans transition and at 25 μg/ml by completely inhibiting C. albicans transition. Cultured C. albicans under biofilm-inducing conditions revealed that both KSL-W and amphotericin B significantly decreased biofilm formation at 2, 4, and 6 days of culture. KSL-W also disrupted mature C. albicans biofilms. The effect of KSL-W on C. albicans growth, transition, and biofilm formation/disruption may thus occur through gene modulation, as the expression of various genes involved in C. albicans growth, transition and biofilm formation were all downregulated when C. albicans was treated with KSL-W. The effect was greater when C. albicans was cultured under hyphae-inducing conditions.

Conclusions

These data provide new insight into the efficacy of KSL-W against C. albicans and its potential use as an antifungal therapy.

【 授权许可】

   
2013 Theberge et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Arendorf TM, Walker DM: The prevalence and intra-oral distribution of Candida albicans in man. Arch Oral Biol 1980, 25:1-10.
• [2]Cannon RD, Chaffin WL: Oral colonization by Candida albicans. Crit Rev Oral Biol Med 1999, 10:359-383.
• [3]Sudbery P, Gow N, Berman J: The distinct morphogenic states of Candida albicans. Trends Microbiol 2004, 12:317-324.
• [4]Nobile CJ, Nett JE, Andes DR, Mitchell AP: Function of Candida albicans adhesin Hwp1 in biofilm formation. Eukaryot Cell 2006, 5:1604-1610.
• [5]Li F, Palecek SP: EAP1, a Candida albicans gene involved in binding human epithelial cells. Eukaryot Cell 2003, 2:1266-1273.
• [6]Sohn K, Urban C, Brunner H, Rupp S: EFG1 is a major regulator of cell wall dynamics in Candida albicans as revealed by DNA microarrays. Mol Microbiol 2003, 47:89-102.
• [7]Stoldt VR, Sonneborn A, Leuker CE, Ernst JF: Efg1p, an essential regulator of morphogenesis of the human pathogen Candida albicans, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi. EMBO J 1997, 16:1982-1991.
• [8]Lo HJ, Köhler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR: Nonfilamentous C. albicans mutants are avirulent. Cell 1997, 90:939-949.
• [9]Schaller M, Borelli C, Korting HC, Hube B: Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 2005, 48:365-377.
• [10]Décanis N, Tazi N, Correia A, Vilanova M, Rouabhia M: Farnesol, a fungal quorum-sensing molecule triggers Candida albicans morphological changes by down-regulating the expression of different secreted aspartyl proteinase genes. Open Microbiol J 2011, 5:119-126.
• [11]Naglik JR, Challacombe SJ, Hube B: Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003, 67:400-428.
• [12]Hube B, Naglik J: Candida albicans proteinases: resolving the mystery of a gene family. Microbiology 2001, 147:1997-2005.
• [13]White TC, Miyasaki SH, Agabian N: Three distinct secreted aspartyl proteinases in Candida albicans. J Bacteriol 1993, 175:6126-6133.
• [14]White TC, Agabian N: Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J Bacteriol 1995, 177:5215-5221.
• [15]Albrecht A, Felk A, Pichova I, Naglik JR, Schaller M, de Groot P, Maccallum D, Odds FC, Schäfer W, Klis F, Monod M, Hube B: Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. J Biol Chem 2006, 281(2):688-694.
• [16]van der Weerden NL, Bleackley MR, Anderson MA: Properties and mechanisms of action of naturally occurring antifungal peptides. Cell Mol Life Sci 2013, 70(19):3545-3570.
• [17]Fjell CD, Hiss JA, Hancock RE, Schneider G: Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 2012, 11:37-51.
• [18]Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ: Antimicrobial peptides for therapeutic applications: a review. Molecules 2012, 17:12276-12286.
• [19]Campbell EL, Serhan CN, Colgan SP: Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators. J Immunol 2011, 187:3475-3481.
• [20]Lehrer RI, Lu W: alpha-Defensins in human innate immunity. Immunol Rev 2012, 245:84-112.
• [21]Mehra T, Koberle M, Braunsdorf C, Mailander-Sanchez D, Borelli C, et al.: Alternative approaches to antifungal therapies. Exp Dermatol 2012, 21:778-782.
• [22]Zhu S: Discovery of six families of fungal defensin-like peptides provides insights into origin and evolution of the CSalphabeta defensins. Mol Immunol 2008, 45:828-838.
• [23]Batoni G, Maisetta G, Brancatisano FL, Esin S, Campa M: Use of antimicrobial peptides against microbial biofilms: advantages and limits. Curr Med Chem 2011, 18:256-279.
• [24]Dziarski R, Gupta D: Review: Mammalian peptidoglycan recognition proteins (PGRPs) in innate immunity. Innate Immun 2010, 16:168-174.
• [25]Taraszkiewicz A, Fila G, Grinholc M, Nakonieczna J: Innovative strategies to overcome biofilm resistance. Biomed Res Int 2013, 2013:150653. doi: 10.1155/2013/150653
• [26]Cota-Arriola O, Cortez-Rocha MO, Burgos-Hernandez A, Ezquerra-Brauer JM, Plascencia-Jatomea M: Controlled release matrices and micro/nanoparticles of chitosan with antimicrobial potential: development of new strategies for microbial control in agriculture. J Sci Food Agric 2013, 93:1525-1536.
• [27]Dhople V, Krukemeyer A, Ramamoorthy A: The human beta-defensin-3, an antibacterial peptide with multiple biological functions. Biochim Biophys Acta 2006, 1758:1499-1512.
• [28]Joly S, Maze C, McCray PB Jr, Guthmiller JM: Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J Clin Microbiol 2004, 42:1024-1029.
• [29]Mooney C, Haslam NJ, Pollastri G, Shields DC: Towards the improved discovery and design of functional peptides: common features of diverse classes permit generalized prediction of bioactivity. PLoS One 2012, 7:e45012.
• [30]Na DH, Faraj J, Capan Y, Leung KP, DeLuca PP: Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity. Pharm Res 2007, 24:1544-1550.
• [31]Hong SY, Park TG, Lee KH: The effect of charge increase on the specificity and activity of a short antimicrobial peptide. Peptides 2001, 22:1669-1674.
• [32]Oh JE, Hong SY, Lee KH: Structure-activity relationship study: short antimicrobial peptides. J Pept Res 1999, 53:41-46.
• [33]Concannon SP, Crowe TD, Abercrombie JJ, Molina CM, Hou P, et al.: Susceptibility of oral bacteria to an antimicrobial decapeptide. J Med Microbiol 2003, 52:1083-1093.
• [34]Leung KP, Crowe TD, Abercrombie JJ, Molina CM, Bradshaw CJ, et al.: Control of oral biofilm formation by an antimicrobial decapeptide. J Dent Res 2005, 84:1172-1177.
• [35]Baker PJ, Coburn RA, Genco RJ, Evans RT: The in vitro inhibition of microbial growth and plaque formation by surfactant drugs. J Periodontal Res 1978, 13:474-485.
• [36]Semlali A, Leung KP, Curt S, Rouabhia M: Antimicrobial decapeptide KSL-W attenuates Candida albicans virulence by modulating its effects on Toll-like receptor, human β-defensin, and cytokine expression by engineered human oral mucosa. Peptides 2011, 32(5):859-867.
• [37]Okkers DJ, Dicks LM, Silvester M, Joubert JJ, Odendaal HJ: Characterization of pentocin TV35b, a bacteriocin-like peptide isolated from Lactobacillus pentosus with a fungistatic effect on Candida albicans. J Appl Microbiol 1999, 87:726-734.
• [38]Dixon DR, Jeffrey NR, Dubey VS, Leung KP: Antimicrobial peptide inhibition of Porphyromonas gingivalis 381-induced hemagglutination is improved with a synthetic decapeptide. Peptides 2009, 30:2161-2167.
• [39]Raines SM, Rane HS, Bernardo SM, Binder JL, Lee SA, et al.: Deletion of Vacuolar Proton-translocating ATPase Voa Isoforms Clarifies the Role of Vacuolar pH as a Determinant of Virulence-associated Traits in Candida albicans. J Biol Chem 2013, 288:6190-6201.
• [40]Ariyachet C, Solis NV, Liu Y, Prasadarao NV, Filler SG, et al.: SR-Like RNA-Binding Protein Slr1 Affects Candida albicans Filamentation and Virulence. Infect Immun 2013, 81:1267-1276.
• [41]Décanis N, Savignac K, Rouabhia M: Farnesol promotes epithelial cell defense against Candida albicans through Toll-like receptor 2 expression, interleukin-6 and human beta-defensin 2 production. Cytokine 2009, 45:132-140.
• [42]Zhang J, Silao FG, Bigol UG, Bungay AA, Nicolas MG, et al.: Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae. PLoS One 2012, 7:e44192.
• [43]Koshlukova SE, Araujo MWB, Baev D, Edgerton M: Released ATP is an extracellular cytotoxic mediator in salivary histatin 5-induced killing ofCandida albicans. Infect Immun 2000, 68:6848-6856.
• [44]Vylkova S, Jang WS, Li W, Nayyar N, Edgerton M: Histatin 5 initiates osmotic stress response in Candida albicans via activation of the Hog1 mitogen-activated protein kinase pathway. Eukaryot Cell 2007, 6:1876-1888.
• [45]Jang WS, Bajwa JS, Sun JN, Edgerton M: Salivary histatin 5 internalization by translocation, but not endocytosis, is required for fungicidal activity in Candida albicans. Mol Microbiol 2010, 77:354-370.
• [46]Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL: Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol 2001, 18:163-170.
• [47]Banerjee M, Uppuluri P, Zhao XR, Carlisle PL, Vipulanandan G, et al.: Expression of UME6, a key regulator of Candida albicans hyphal development, enhances biofilm formation via Hgc1- and Sun41-dependent mechanisms. Eukaryot Cell 2013, 12:224-232.
• [48]da Silva BR, de Freitas VA, Carneiro VA, Arruda FV, Lorenzon EN, et al.: Antimicrobial activity of the synthetic peptide Lys-a1 against oral streptococci. Peptides 2013, 42C:78-83.
• [49]Beckloff N, Laube D, Castro T, Furgang D, Park S, et al.: Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens. Antimicrob Agents Chemother 2007, 51:4125-4132.
• [50]Patrzykat A, Friedrich CL, Zhang L, Mendoza V, Hancock RE: Sublethal concentrations of pleurocidin-derived antimicrobial peptides inhibit macromolecular synthesis in Escherichia coli. Antimicrob Agents Chemother 2002, 46:605-614.
• [51]Mason AJ, Chotimah IN, Bertani P, Bechinger B: A spectroscopic study of the membrane interaction of the antimicrobial peptide Pleurocidin. Mol Membr Biol 2006, 23:185-194.
• [52]Bauerova V, Pichova I, Hruskova-Heidingsfeldova O: Nitrogen source and growth stage of Candida albicans influence expression level of vacuolar aspartic protease Apr1p and carboxypeptidase Cpy1p. Can J Microbiol 2012, 58:678-681.
• [53]Cleary IA, Lazzell AL, Monteagudo C, Thomas DP, Saville SP: BRG1 and NRG1 form a novel feedback circuit regulating Candida albicans hypha formation and virulence. Mol Microbiol 2012, 85:557-573.
• [54]Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, et al.: A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 2012, 148:126-138.
• [55]Murad AM, Leng P, Straffon M, Wishart J, Macaskill S, et al.: NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in Candida albicans. EMBO J 2001, 20:4742-4752.
• [56]Braun BR, Kadosh D, Johnson AD: NRG1, a repressor of filamentous growth in C.albicans, is down-regulated during filament induction. EMBO J 2001, 20:4753-4761.
• [57]Li F, Svarovsky MJ, Karlsson AJ, Wagner JP, Marchillo K, et al.: Eap1p, an adhesin that mediates Candida albicans biofilm formation in vitro and in vivo. Eukaryot Cell 2007, 6:931-939.
• [58]Sharkey LL, McNemar MD, Saporito-Irwin SM, Sypherd PS, Fonzi WA: HWP1 functions in the morphological development of Candida albicans downstream of EFG1, TUP1, and RBF1. J Bacteriol 1999, 181:5273-5279.
• [59]Staniszewska M, Bondaryk M, Siennicka K, Kurek A, Orlowski J, et al.: In vitro study of secreted aspartyl proteinases Sap1 to Sap3 and Sap4 to Sap6 expression in Candida albicans pleomorphic forms. Pol J Microbiol 2012, 61:247-256.
• [60]Lian CH, Liu WD: Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis. Mycoses 2007, 50:383-390.
• [61]Hube B, Monod M, Schofield DA, Brown AJ, Gow NA: Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol Microbiol 1994, 14:87-99.
• [62]Puri S, Kumar R, Chadha S, Tati S, Conti HR, et al.: Secreted aspartic protease cleavage of Candida albicans Msb2 activates Cek1 MAPK signaling affecting biofilm formation and oropharyngeal candidiasis. PLoS One 2012, 7:e46020.
• [63]Hong SY, Oh JE, Kwon M, Choi MJ, Lee JH, et al.: Identification and characterization of novel antimicrobial decapeptides generated by combinatorial chemistry. Antimicrob Agents Chemother 1998, 42:2534-2541.
• [64]Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986, 89:271-277.
• [65]Li L, Zhang C, Konopka JB: A Candida albicans temperature-sensitive cdc12-6 mutant identifies roles for septins in selection of sites of germ tube formation and hyphal morphogenesis. Eukaryot Cell 2012, 11:1210-1218.